DIGITAL DOSE INHALER MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In July 2023, Teva UK Limited, a subsidiary company of Teva Pharmaceutical Industries Ltd., launched GoResp Digihaler (budesonide / formoterol fumarate dihydrate) in the U.K. GoResp Digihaler is the first integrated inhaler device with built-in sensors that detect and record objective data on the patient’s use and ability to use their inhaler, including inspiratory flow classification.
• In June 2023, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, in collaboration with Teva Pharmaceutical Industries Ltd. launched a new program to improve access to the Digihaler family of inhalers to support asthma management
• In January 2020, Cognita Labs, a medical device company, announced that the U.S. Food and Drug Administration had approved digital inhaler sensor for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and other pulmonary conditions. The inhaler fuses digital technology with traditional metered dose inhalers (MDIs), which guides patients using live audio-visual cues to help them use the device correctly and regularly, crucial for effective therapy and avoidance of flare-ups.